40425_2019_823_MOESM2_ESM.pdf (791.46 kB)
MOESM2 of Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition
journal contribution
posted on 2019-12-07, 04:30 authored by Julie Voeller, Amy Erbe, Jacob Slowinski, Kayla Rasmussen, Peter Carlson, Anna Hoefges, Sabrina VandenHeuvel, Ashley Stuckwisch, Xing Wang, Stephen Gillies, Ravi Patel, Alvin Farrel, Jo Rokita, John Maris, Jacquelyn Hank, Zachary Morris, Alexander Rakhmilevich, Paul SondelAdditional file 2: Figure S2. Response of immunologically cold, syngeneic 9464D-GD2 tumors in C57Bl/6 mice obtained from Jackson (JAX) compared to Taconic (TAC). Tumor growth curves are shown for JAX mice bearing intradermal 9464D-GD2 tumors (about 50mm3) that were untreated or treated with RT alone or RT and combined IT-IC, anti-CTLA-4, CpG and anti-CD40. Tumor-free mice on day 60 are denoted as number of CR of total mice in the group. For each treatment group tested in TAC mice (shown in Fig. 4a) and JAX mice (shown here) in the same experiment, there was no significant difference in tumor response between TAC versus JAX mice.
